Titan Biotech Ltd
BSE:524717
Titan Biotech Ltd
BSE:524717
Price:
415.85
INR
3.92%
Market Closed
Market Cap:
₹17.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Titan Biotech Ltd
BSE:524717
|
IN |
|
T
|
Tharisa PLC
JSE:THA
|
CY |
|
Cybrid Technologies Inc
SSE:603212
|
CN |
|
China Tianrui Group Cement Co Ltd
HKEX:1252
|
CN |
|
Mitsui E&S Holdings Co Ltd
TSE:7003
|
JP |
|
A
|
Agilyx ASA
OSE:AGLX
|
NO |
|
Beijer Alma AB
STO:BEIA B
|
SE |
|
AP Moeller - Maersk A/S
CSE:MAERSK B
|
DK |
|
Filo Mining Corp
TSX:FIL
|
CA |
Balance Sheet
Balance Sheet Decomposition
Titan Biotech Ltd
Titan Biotech Ltd
Balance Sheet Decomposition is not available for
Titan Biotech Ltd
Titan Biotech Ltd
Balance Sheet
Titan Biotech Ltd
Titan Biotech Ltd
Currency: INR
| Mar-2012 | Mar-2013 | Mar-2014 | Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
4
|
20
|
20
|
4
|
36
|
43
|
12
|
20
|
19
|
55
|
68
|
49
|
29
|
51
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
55
|
68
|
49
|
28
|
51
|
|
| Cash Equivalents |
4
|
20
|
20
|
4
|
36
|
43
|
12
|
20
|
19
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
56
|
30
|
63
|
78
|
72
|
75
|
78
|
92
|
119
|
190
|
166
|
221
|
222
|
207
|
|
| Accounts Receivables |
37
|
26
|
56
|
64
|
59
|
63
|
78
|
92
|
119
|
181
|
164
|
210
|
187
|
188
|
|
| Other Receivables |
19
|
4
|
7
|
14
|
12
|
12
|
0
|
0
|
0
|
9
|
3
|
11
|
36
|
19
|
|
| Inventory |
56
|
54
|
69
|
111
|
110
|
145
|
176
|
211
|
280
|
342
|
347
|
366
|
469
|
525
|
|
| Other Current Assets |
0
|
14
|
14
|
20
|
21
|
32
|
27
|
27
|
25
|
2
|
56
|
48
|
52
|
7
|
|
| Total Current Assets |
115
|
118
|
165
|
213
|
238
|
295
|
293
|
351
|
442
|
588
|
638
|
683
|
722
|
790
|
|
| PP&E Net |
98
|
103
|
111
|
120
|
158
|
219
|
268
|
289
|
311
|
338
|
385
|
491
|
545
|
588
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
338
|
385
|
491
|
545
|
588
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
116
|
136
|
162
|
189
|
230
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
63
|
5
|
4
|
3
|
9
|
|
| Long-Term Investments |
2
|
2
|
3
|
3
|
4
|
5
|
5
|
6
|
6
|
0
|
42
|
157
|
285
|
348
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
17
|
10
|
10
|
10
|
10
|
|
| Total Assets |
215
N/A
|
223
+4%
|
279
+25%
|
335
+20%
|
401
+20%
|
522
+30%
|
568
+9%
|
647
+14%
|
760
+17%
|
1 007
+32%
|
1 081
+7%
|
1 345
+24%
|
1 566
+16%
|
1 747
+12%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
47
|
16
|
15
|
14
|
17
|
14
|
11
|
21
|
41
|
37
|
42
|
55
|
34
|
52
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
3
|
6
|
6
|
|
| Short-Term Debt |
8
|
16
|
31
|
55
|
71
|
73
|
71
|
97
|
113
|
83
|
47
|
55
|
63
|
15
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
8
|
8
|
10
|
14
|
20
|
16
|
9
|
8
|
|
| Other Current Liabilities |
12
|
25
|
39
|
35
|
38
|
36
|
20
|
31
|
40
|
57
|
58
|
74
|
80
|
95
|
|
| Total Current Liabilities |
66
|
57
|
84
|
105
|
127
|
123
|
110
|
158
|
204
|
193
|
169
|
204
|
191
|
177
|
|
| Long-Term Debt |
10
|
20
|
39
|
22
|
43
|
152
|
179
|
132
|
116
|
63
|
22
|
14
|
11
|
4
|
|
| Deferred Income Tax |
2
|
1
|
3
|
4
|
5
|
6
|
8
|
11
|
12
|
14
|
13
|
12
|
14
|
15
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
11
|
11
|
12
|
16
|
24
|
37
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
16
|
10
|
13
|
13
|
14
|
16
|
15
|
16
|
|
| Total Liabilities |
78
N/A
|
78
+1%
|
126
+60%
|
130
+4%
|
185
+42%
|
292
+57%
|
325
+11%
|
326
+0%
|
368
+13%
|
320
-13%
|
218
-32%
|
246
+13%
|
231
-6%
|
213
-8%
|
|
| Equity | |||||||||||||||
| Common Stock |
70
|
70
|
70
|
77
|
77
|
77
|
77
|
83
|
83
|
83
|
83
|
83
|
83
|
83
|
|
| Retained Earnings |
67
|
74
|
83
|
127
|
138
|
153
|
166
|
239
|
309
|
605
|
692
|
928
|
1 162
|
1 361
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
87
|
87
|
87
|
87
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
4
|
|
| Total Equity |
138
N/A
|
145
+5%
|
153
+6%
|
205
+33%
|
215
+5%
|
230
+7%
|
244
+6%
|
322
+32%
|
392
+22%
|
688
+75%
|
862
+25%
|
1 099
+27%
|
1 335
+21%
|
1 534
+15%
|
|
| Total Liabilities & Equity |
215
N/A
|
223
+4%
|
279
+25%
|
335
+20%
|
401
+20%
|
522
+30%
|
568
+9%
|
647
+14%
|
760
+17%
|
1 007
+32%
|
1 081
+7%
|
1 345
+24%
|
1 566
+16%
|
1 747
+12%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
7
|
7
|
7
|
8
|
8
|
8
|
8
|
8
|
8
|
8
|
8
|
41
|
41
|
41
|
|
Switch to:
Switch to:
See Also
Discover More
